Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Mudcat who wrote (28431)	3/1/1999 7:05:00 PM
From: jayhawk969	Read Replies (2) \| Respond to of 32384

Cheryl and gang, The rapid release of this information tells me that the fourth quarter is without milestones. I now fully expect a large loss. Cheryl when do you project the earnings announcement? J.D.

To: Mudcat who wrote (28431)	3/1/1999 7:47:00 PM
From: RXGOLF	Read Replies (1) \| Respond to of 32384

Thanks for the news! Had to be gone all day and was clueless! Thanks, Greg

To: Mudcat who wrote (28431)	3/2/1999 4:02:00 AM
From: Cheryl Galt	Respond to of 32384

>> Finally a milestone payment! << Yes! I'm glad to see REVENUE. I don't care if Ligand is profitable by a certain date. ---------------------------------------------------------------- ASSUMING that Targretin shows good anti-tumor activity in the Ph II ABC trial .... I DO care that Ligand has enough revenue to carry through until Targretin is making money for treatment of breast cancer -- before surgery, to reduce the tumor -- short-term after surgery, to eliminate residual cancer -- after recurrence. I do NOT want to see Ligand run short of funds before Targretin carries it to a new phase. I do NOT want to see Targretin (and too many other of Ligand's cancer molecules) farmed out. In my opinion, this year is make-or-break -- and it will be a tight financial squeeze -- recently made a bit tighter by the Lilly decision and the Supergen challenge. -- These two events increased the risk/reward ratio, by my calculations. (By the way, Nipent has been on the market since 1991, for HCL -- so it could be prescribed off label for CTCL. I hope Ligand has already sold the Ontak it made last year, and look forward to the "bottle reports.") And Mudcat, I'm sorry I way over-reacted the other day. Complex indeed! Regards, Cheryl